NASDAQ:COLLCollegium Pharmaceutical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Collegium Pharmaceutical Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $23.18 -0.06 (-0.26 %) (As of 05/28/2020 04:00 PM ET) Add Compare Share Today's Range$23.16Now: $23.18▼$23.9050-Day Range$17.56MA: $20.46▼$23.5152-Week Range$10.01Now: $23.18▼$25.59Volume303,704 shsAverage Volume618,170 shsMarket Capitalization$795.91 millionP/E RatioN/ADividend YieldN/ABeta1.07 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting. The company offers Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. Furhter, it offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingCollegium Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.50, Collegium Pharmaceutical has a potential upside of 40.2% from its current price of $23.18.Amount of Analyst CoverageCollegium Pharmaceutical has only been the subject of 3 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesCollegium Pharmaceutical has received 313 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCollegium Pharmaceutical has received 313 “underperform” votes. (Add your “underperform” vote.)Community SentimentCollegium Pharmaceutical has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote “Outperform” if you believe COLL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe COLL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCollegium Pharmaceutical does not currently pay a dividend.Dividend GrowthCollegium Pharmaceutical does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Collegium Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $689,838.00 in company stock.Percentage Held by InsidersOnly 8.08% of the stock of Collegium Pharmaceutical is held by insiders. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Collegium Pharmaceutical are expected to grow by 61.25% in the coming year, from $1.60 to $2.58 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Collegium Pharmaceutical is -61.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Collegium Pharmaceutical is -61.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioCollegium Pharmaceutical has a PEG Ratio of 0.73. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioCollegium Pharmaceutical has a P/B Ratio of 5.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 3.1 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.80 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:COLL Previous Symbol CUSIPN/A CIK1267565 Webwww.collegiumpharma.com Phone781-713-3699Debt Debt-to-Equity Ratio1.77 Current Ratio0.92 Quick Ratio0.85Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio14.49 P/E Growth0.73 Sales & Book Value Annual Sales$296.70 million Price / Sales2.68 Cash FlowN/A Price / Cash FlowN/A Book Value$4.11 per share Price / Book5.64Profitability EPS (Most Recent Fiscal Year)($0.68) Net Income$-22,720,000.00 Net Margins-4.21% Return on Equity-12.62% Return on Assets-3.25%Miscellaneous Employees266 Outstanding Shares34,336,000Market Cap$795.91 million Next Earnings Date8/5/2020 (Estimated) OptionableOptionable NASDAQ:COLL Rates by TradingView Receive COLL News and Ratings via Email Sign-up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions How has Collegium Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)? Collegium Pharmaceutical's stock was trading at $17.57 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, COLL stock has increased by 31.9% and is now trading at $23.18. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Collegium Pharmaceutical? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Collegium Pharmaceutical. When is Collegium Pharmaceutical's next earnings date? Collegium Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Collegium Pharmaceutical. How were Collegium Pharmaceutical's earnings last quarter? Collegium Pharmaceutical Inc (NASDAQ:COLL) posted its quarterly earnings data on Thursday, May, 7th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter, missing analysts' consensus estimates of $0.66 by $0.65. The specialty pharmaceutical company had revenue of $76.51 million for the quarter, compared to analyst estimates of $76.64 million. Collegium Pharmaceutical had a negative return on equity of 12.62% and a negative net margin of 4.21%. Collegium Pharmaceutical's quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.29) earnings per share. View Collegium Pharmaceutical's earnings history. What guidance has Collegium Pharmaceutical issued on next quarter's earnings? Collegium Pharmaceutical updated its FY 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $300-320 million, compared to the consensus revenue estimate of $318.44 million. What price target have analysts set for COLL? 8 Wall Street analysts have issued twelve-month price objectives for Collegium Pharmaceutical's stock. Their forecasts range from $22.00 to $43.00. On average, they expect Collegium Pharmaceutical's share price to reach $32.50 in the next twelve months. This suggests a possible upside of 40.2% from the stock's current price. View analysts' price targets for Collegium Pharmaceutical. Has Collegium Pharmaceutical been receiving favorable news coverage? News coverage about COLL stock has been trending somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Collegium Pharmaceutical earned a news impact score of -1.8 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutCollegium Pharmaceutical. Who are some of Collegium Pharmaceutical's key competitors? Some companies that are related to Collegium Pharmaceutical include PTC Therapeutics (PTCT), Amicus Therapeutics (FOLD), Axsome Therapeutics (AXSM), Uniqure (QURE), Arena Pharmaceuticals (ARNA), HUTCHISON CHINA/S (HCM), Amarin (AMRN), Taro Pharmaceutical Industries (TARO), Insmed (INSM), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Intercept Pharmaceuticals (ICPT), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX) and Ra Pharmaceuticals (RARX). View all competitors. What other stocks do shareholders of Collegium Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), AbbVie (ABBV), NVIDIA (NVDA), Canopy Growth (CGC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Bausch Health Companies (BHC), Intercept Pharmaceuticals (ICPT), Advanced Micro Devices (AMD) and GW Pharmaceuticals PLC- (GWPH). Who are Collegium Pharmaceutical's key executives? Collegium Pharmaceutical's management team includes the following people: Mr. Michael Thomas Heffernan, Co-Founder & Chairman (Age 55)Mr. Joseph J. Ciaffoni, Pres, CEO & Director (Age 48)Mr. Paul J. Brannelly, Exec. VP & CFO (Age 46)Dr. Alison B. Fleming, Exec. VP & Chief Technology Officer (Age 44)Ms. Shirley R. Kuhlmann, Exec. VP, Gen. Counsel & Sec. (Age 35) When did Collegium Pharmaceutical IPO? (COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers. What is Collegium Pharmaceutical's stock symbol? Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL." Who are Collegium Pharmaceutical's major shareholders? Collegium Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (14.86%), BlackRock Inc. (7.28%), Camber Capital Management LP (5.82%), Franklin Resources Inc. (5.33%), Perceptive Advisors LLC (4.52%) and Rock Springs Capital Management LP (3.42%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan, Paul Brannelly and Scott Dreyer. View institutional ownership trends for Collegium Pharmaceutical. Which institutional investors are selling Collegium Pharmaceutical stock? COLL stock was sold by a variety of institutional investors in the last quarter, including Frazier Management LLC, Rock Springs Capital Management LP, Mackay Shields LLC, Emerald Mutual Fund Advisers Trust, BlackRock Inc., Squarepoint Ops LLC, Alliancebernstein L.P., and UBS Group AG. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan, and Scott Dreyer. View insider buying and selling activity for Collegium Pharmaceutical. Which institutional investors are buying Collegium Pharmaceutical stock? COLL stock was purchased by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Perceptive Advisors LLC, Invesco Ltd., Janus Henderson Group PLC, Vivo Capital LLC, Mesirow Financial Investment Management Equity Management, Acadian Asset Management LLC, and Two Sigma Investments LP. View insider buying and selling activity for Collegium Pharmaceutical. How do I buy shares of Collegium Pharmaceutical? Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Collegium Pharmaceutical's stock price today? One share of COLL stock can currently be purchased for approximately $23.18. How big of a company is Collegium Pharmaceutical? Collegium Pharmaceutical has a market capitalization of $795.91 million and generates $296.70 million in revenue each year. The specialty pharmaceutical company earns $-22,720,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe. What is Collegium Pharmaceutical's official website? The official website for Collegium Pharmaceutical is www.collegiumpharma.com. How can I contact Collegium Pharmaceutical? Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699. This page was last updated on 5/28/2020 by MarketBeat.com Staff
